KRd versus VRd in patients with newly diagnosed multiple myeloma

Bookmark and Share
Published: 6 Dec 2018
Views: 1486
Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA

Dr Ola Landgren speaks to ecancer at ASH 2018 about the results from a study into carfilzomib-lenalidomide-dexamethasone (KRd) versus bortezomib-lenalidomide-dexamethasone (VRd) in newly diagnosed patients with multiple myeloma.

He explains that the CoMMpass study, launched by the Multiple Myeloma Research Foundation (MMRF), can be used to identify patients treated with the KRd and VRd regiments.

Dr Landgren reveals that the event free survival is highly superior for patients treated with KRd.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.